Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FFAR4 | Q5NUL3 | 2/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | KDM1A | O60341 | 1/20 | 0.32 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.31 |
| ▸ | MOGAT2 | Q3SYC2 | 2/20 | 0.31 |
| ▸ | MAOB | P27338 | 1/20 | 0.31 |
| ▸ | OPRL1 | P41146 | 4/20 | 0.31 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.31 |
| ▸ | GYS1 | P13807 | 1/20 | 0.31 |
| ▸ | FFAR1 | O14842 | 2/20 | 0.30 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12739923 | 0.94 | FFAR4 (0.34) | FFAR4MEN1LMNAMAPTKMT2A | |
| SCHEMBL14766073 | 0.92 | FFAR4 (0.33) | FFAR4MEN1LMNAMAPTKMT2A | |
| SCHEMBL12735233 | 0.91 | CYP2C9 (0.35) | FFAR4KDM1ACYP2C9MOGAT2OPRL1 | |
| SCHEMBL12735238 | 0.91 | CYP2C9 (0.34) | FFAR4KDM1ACYP2C9MOGAT2FFAR1 | |
| SCHEMBL12822774 | 0.89 | MEN1 (0.32) | FFAR4MEN1LMNAMAPTKMT2A | |
| SCHEMBL12735212 | 0.89 | FFAR4 (0.35) | FFAR4KDM1ACYP2C9MOGAT2OPRL1 | |
| SCHEMBL12733966 | 0.88 | LMNA (0.38) | FFAR4MEN1LMNAMAPTKMT2A | |
| SCHEMBL12735214 | 0.87 | CYP2C9 (0.36) | FFAR4KDM1ACYP2C9MOGAT2OPRL1 | |
| SCHEMBL10302120 | 0.87 | OPRL1 (0.34) | FFAR4MEN1LMNAMAPTKMT2A | |
| SCHEMBL12736856 | 0.86 | FFAR4 (0.34) | FFAR4MEN1LMNAMAPTKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8394294-B2 | Four-ring liquid crystal compound having lateral fluorine, liquid crystal composition and liquid crystal display device | JNC CORPORATION (JP) | 2013-03-12 | — | — | US | disclosed |
| US-20110090450-A1 | FOUR-RING LIQUID CRYSTAL COMPOUND HAVING LATERAL FLUORINE, LIQUID CRYSTAL COMPOSITION AND LIQUID CRYSTAL DISPLAY DEVICE | JNC CORPORATION (JP) | 2011-04-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110090450-A1 | FOUR-RING LIQUID CRYSTAL COMPOUND HAVING LATERAL FLUORINE, LIQUID CRYSTAL COMPOSITION AND LIQUID CRYSTAL DISPLAY DEVICE | LEF1, LAS1L, EFHD2 | FFAR4 546/4885MEN1 2496/4885LMNA 530/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.